Gastrointestinal Stromal Tumor (GIST)
A gastrointestinal stromal tumor (GIST) is a distinctive type of tumor that arises from specialized pacemaker cells (interstitial cells of Cajal) in the wall of the gastrointestinal tract. GISTs are the most common non-epithelial (mesenchymal) tumors of the GI tract and can occur anywhere from the esophagus to the rectum, though they most commonly develop in the stomach, followed by the small bowel. Their behavior ranges from small, indolent lesions found incidentally to more aggressive tumors that can spread to the liver or peritoneum. GISTs are notable for the important role of specific genetic mutations (particularly in the KIT and PDGFRA genes) in driving tumor growth, which has made them highly responsive to targeted therapies such as imatinib—transforming what was once a difficult-to-treat cancer into a much more manageable condition.
What is it?
The wall of the gastrointestinal tract contains specialized cells called interstitial cells of Cajal (ICCs), which serve as pacemakers for the rhythmic contractions that move food through the bowel. GISTs arise from these cells (or their precursors) and are considered mesenchymal tumors—tumors of connective tissue origin, distinct from carcinomas (which arise from the glandular lining) and lymphomas (which arise from immune cells). Before the recognition of GISTs as a distinct entity in the 1990s, these tumors were often mistakenly classified as leiomyomas (smooth muscle tumors) or leiomyosarcomas, and their unique biology and treatment implications were not appreciated.
The recognition of GISTs as a distinct tumor type has been one of the most important developments in modern cancer care and has revolutionized their treatment. Most GISTs are driven by mutations in specific genes—most commonly the KIT gene (in roughly 80% of cases) and the PDGFRA gene (in roughly 10% of cases). Both KIT and PDGFRA encode proteins called tyrosine kinases that normally regulate cell growth. Mutations in these genes cause the tyrosine kinases to be continuously active, driving tumor growth. This understanding led to the development of targeted therapies (tyrosine kinase inhibitors) that block these abnormal proteins, dramatically improving outcomes.
A small proportion of GISTs (roughly 10–15%) lack mutations in KIT and PDGFRA and are called “wild-type” GISTs. These include tumors with mutations in other genes (such as SDH-deficient GISTs, BRAF-mutant GISTs, NF1-associated GISTs, and others) and generally have different clinical behavior and treatment considerations. Pediatric GISTs are almost always SDH-deficient and behave differently from adult KIT-mutant GISTs.
GISTs can occur anywhere in the gastrointestinal tract but have specific patterns of distribution. The stomach is by far the most common site (about 60%). The small bowel accounts for roughly 30%, with the jejunum and ileum being more common sites within the small bowel than the duodenum. The colon and rectum together account for roughly 5%, and the esophagus is a rare site (less than 5%). GISTs can also occur outside the GI tract in the omentum, mesentery, or retroperitoneum (called extragastrointestinal GISTs, or EGISTs), though most of these are thought to have originated in the GI tract before separating.
Most GISTs occur sporadically without any inherited predisposition, but certain conditions are associated with increased risk:
– Neurofibromatosis type 1 (NF1)—associated with small bowel GISTs, often multiple, occurring at younger ages
– Carney triad—a rare condition involving GISTs (typically in the stomach), pulmonary chondromas, and paragangliomas, more common in young women
– Carney-Stratakis syndrome—an inherited condition involving GISTs and paragangliomas due to SDH gene mutations
– Familial GIST syndrome—very rare inherited GIST predisposition due to germline KIT mutations
Symptoms of GISTs vary widely by location, size, and behavior. Small GISTs (particularly small gastric GISTs) often cause no symptoms and are identified incidentally—during endoscopy performed for other reasons (such as evaluation of reflux symptoms), during imaging performed for unrelated conditions, or at surgery for other reasons. Small incidental GISTs (called microGISTs when very small) are actually relatively common findings, particularly in the stomachs of older adults, and many of these never progress to clinically significant disease.
Larger or more aggressive GISTs typically cause symptoms related to their location and effects on the bowel:
Gastric GISTs may cause gastrointestinal bleeding (visible bleeding or, more commonly, occult bleeding causing iron-deficiency anemia over time), abdominal pain or discomfort, sensation of fullness, nausea, and, with larger tumors, a palpable abdominal mass.
Small bowel GISTs may cause abdominal pain, gastrointestinal bleeding (particularly with tumor ulceration), symptoms of small bowel obstruction, intussusception (with the tumor as the leading edge), and, in some cases, acute complications such as tumor rupture.
Colon and rectal GISTs may cause bleeding, changes in bowel habits, or pelvic discomfort.
Esophageal GISTs may cause difficulty swallowing.
Systemic symptoms of advanced disease—such as unintended weight loss and fatigue—may occur with advanced disease.
Diagnosis of a GIST typically involves several components.
Imaging is central. CT of the abdomen and pelvis with intravenous contrast is the primary imaging test and shows the tumor’s size, location, relationship to the bowel wall (often bulging outward, with the bulk of the tumor extraluminal), enhancement pattern, and evidence of any spread. MRI provides similar information without ionizing radiation and can be useful in specific circumstances.
Endoscopy allows direct visualization of GISTs that bulge into the lumen. Upper endoscopy evaluates the esophagus, stomach, and duodenum. Colonoscopy evaluates the colon and rectum. Specialized techniques (capsule endoscopy or deep enteroscopy) may be needed for evaluation of small bowel GISTs. Typical endoscopic appearance is a smooth submucosal bulge with intact overlying mucosa (unlike ulcerating carcinomas or polyps).
Endoscopic ultrasound (EUS) is particularly useful for evaluating GISTs. It provides detailed visualization of the bowel wall layers and can characterize the tumor’s origin, size, and features. EUS-guided fine-needle biopsy can obtain tissue for diagnosis while preserving the tumor for surgical resection when appropriate. Biopsy provides confirmation of the diagnosis and allows molecular testing.
Molecular testing of the tumor is essential and typically includes:
– Immunohistochemistry for CD117 (KIT), DOG1, and other markers—positive in most GISTs and helps distinguish them from other tumors
– Testing for KIT mutations (particularly in exon 11, 9, 13, 17)—the most common driver mutations and guide treatment
– Testing for PDGFRA mutations (particularly D842V, which is resistant to imatinib but responsive to newer agents such as avapritinib)
– Testing for SDH deficiency in specific cases
– Other tests in specific circumstances
Risk stratification is important for GISTs because their behavior varies widely. Several classification systems (such as the National Institutes of Health Consensus Criteria, the Armed Forces Institute of Pathology criteria, and the Miettinen and Lasota classification) use factors including tumor size, mitotic rate (a measure of how quickly cells are dividing), location (with small bowel GISTs generally behaving more aggressively than gastric GISTs of similar size and mitotic rate), and rupture status to estimate the risk of recurrence and guide treatment decisions.
Staging typically includes CT of the chest, abdomen, and pelvis to evaluate for distant spread, particularly to the liver and peritoneum (the two most common sites of GIST metastasis). GISTs rarely spread to lymph nodes, in contrast to most other GI cancers, and this affects the surgical approach.
Important to Know
Management of GIST has been revolutionized by the availability of effective targeted therapies over the past two decades, transforming outcomes for many patients. Care is best delivered by multidisciplinary teams that include surgeons with experience in GIST, medical oncologists (particularly those specializing in sarcoma or GIST), gastroenterologists, radiologists, pathologists with expertise in molecular testing, and, when needed, other specialists.
For small, low-risk gastric GISTs identified incidentally (particularly those less than 2 cm without concerning features on endoscopic ultrasound), observation with surveillance endoscopy may be appropriate in selected patients rather than immediate surgical resection. This reflects the frequent finding of small microGISTs on autopsy studies and the low progression risk of many small gastric GISTs. The decision is individualized based on tumor characteristics, patient factors, and preferences.
For localized GISTs requiring treatment, surgical resection with negative margins is the mainstay of curative treatment. Surgery typically involves removal of the tumor with a rim of surrounding normal tissue, without the need for wide lymph node dissection (since GISTs rarely spread to lymph nodes). Various surgical approaches are used depending on the location, size, and specific circumstances:
– Gastric GISTs may be treated with wedge resection or partial gastrectomy, often laparoscopically or robotically for smaller tumors
– Small bowel GISTs are typically treated with segmental resection of the affected bowel
– Colon and rectal GISTs may be treated with segmental resection
– Esophageal GISTs may require esophagectomy for larger tumors, though small tumors may be treated with local resection
Care during surgery is important because GISTs can be fragile and rupture during handling, which significantly worsens prognosis. Surgeons experienced in GIST take specific measures to avoid tumor rupture during resection.
Molecular testing of the resected tumor is essential and guides subsequent treatment decisions, particularly the choice of adjuvant therapy for higher-risk tumors.
Adjuvant imatinib after surgery is standard for patients with high-risk GISTs. Risk stratification is based on factors including tumor size, mitotic rate, location, and rupture status. Adjuvant imatinib for at least 3 years has been shown to improve survival compared with 1 year of treatment (based on trials such as SSGXVIII/AIO), and longer durations (or in some cases indefinite therapy) are considered in the highest-risk patients. Imatinib dosing is guided by the specific KIT mutation—tumors with KIT exon 9 mutations often benefit from higher doses.
For patients with tumors harboring PDGFRA D842V mutations, imatinib is not effective, and avapritinib is the appropriate targeted therapy.
For unresectable or metastatic GISTs, imatinib is the standard first-line treatment. Most patients respond to imatinib, often dramatically, with tumor shrinkage and prolonged disease control. Treatment is typically continued indefinitely as long as it remains effective and tolerated. Response is often evaluated with CT (sometimes supplemented by PET/CT to assess early treatment response). Careful monitoring for progression is important.
When imatinib eventually fails (usually due to development of resistance mutations), other tyrosine kinase inhibitors are used sequentially:
– Sunitinib is standard second-line therapy
– Regorafenib is standard third-line therapy
– Ripretinib is approved for fourth-line therapy in patients who have progressed on the earlier agents
– Avapritinib is used for PDGFRA D842V mutations and for the more advanced setting in some GISTs
For patients with certain rare or specific GIST subtypes (such as SDH-deficient GISTs, BRAF-mutant GISTs, NF1-associated GISTs), the treatment approach differs from standard KIT-mutant GISTs, and clinical trials or specialized approaches may be important.
For patients with limited metastatic disease, surgical resection of metastases may be considered in specific circumstances, though systemic therapy generally remains the mainstay for metastatic disease. Cytoreductive procedures may be considered in specific settings.
For patients with hereditary GIST syndromes (such as familial GIST, Carney-Stratakis syndrome, or Carney triad), coordinated care includes genetic counseling, family screening, and management of associated conditions.
Neurofibromatosis type 1 patients require ongoing surveillance for GISTs and other associated tumors, and coordinated care with genetics and specialty medicine.
Response to treatment is typically assessed using imaging (CT, sometimes PET/CT for early assessment) at regular intervals. Tumors may show initial improvement followed by stabilization, and specific patterns of response are important to recognize (a tumor that decreases in enhancement on CT without significantly shrinking is often still responding).
Long-term follow-up is important because of the risk of recurrence, particularly with higher-risk tumors. Standard surveillance typically includes clinical assessment and CT imaging at regular intervals, with the frequency depending on the risk category and time from treatment.
Side effects of tyrosine kinase inhibitors can include swelling (particularly around the eyes), muscle cramps, gastrointestinal symptoms, skin changes, fatigue, and, less commonly, more significant effects. Management often involves supportive measures and, in some cases, dose adjustments.
Care during pregnancy in patients with GIST requires special attention. Some treatments have implications for the fetus, and coordination with obstetrics, maternal-fetal medicine, and oncology is essential.
For patients considering fertility preservation before treatment, coordination with reproductive medicine is important.
Nutritional support and physical rehabilitation may be important, particularly after major surgery or during long-term treatment.
Care is best coordinated by multidisciplinary teams at centers with experience in GIST. Given the availability of multiple effective targeted therapies and the importance of molecular testing, care by teams with specific GIST expertise offers meaningful benefits. Clinical trials continue to be important for the ongoing development of new treatments.
Patient education plays an essential role. Understanding the diagnosis, the specific molecular characteristics of the tumor, the rationale for the recommended treatment plan (including the importance of adherence to tyrosine kinase inhibitors), the meaning of imaging and laboratory findings, treatment side effects, and warning signs of complications or recurrence all contribute to better outcomes. Patient support groups and organizations focused on GIST can provide valuable information and community.
Red flag symptoms include severe abdominal pain, symptoms of bowel obstruction (severe abdominal pain, distention, vomiting, inability to pass stool or gas), significant gastrointestinal bleeding (large amounts of visible blood, black tarry stools, or lightheadedness with bleeding), signs of tumor rupture (sudden severe abdominal pain, low blood pressure), high fever with signs of severe infection, difficulty breathing (which may suggest lung problems), significant swelling that is worsening or associated with breathing problems, sudden severe pain elsewhere in the body, or rapid clinical deterioration. These warrant prompt or urgent medical evaluation.